Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Q2 2015 Earnings Presentation

24 slides from Sucampo Pharmaceuticals's earnings presentation, Aug 5, 2015

  1. Slide 1: Q2 2015 Corporate Update and Financial Results

    Q2 2015 Corporate Update and Financial Results August 5, 2015 $ SUCAMPO ‘The Science of Innovation

  2. Slide 2: Introductions and Forward-Looking Statements

    luctions and Forward= ig Statements Silvia Taylor Senior Vice President, Investor Relations and Corporate Communications ¢ 9 SUCAMPO ‘The Science of Innovation

  3. Slide 3: Agenda

    Agenda | eae eon ornare ooking Silvia Taylor Corporate Update Peter Greenleaf | Pipeline Update : Peter Kiener, D. Phil Financial Performance Andrew Smith Closing Remarks Peter Greenleaf $F SUCANES sansa

  4. Slide 4: Forward-Looking Statements

    Forward-Looking Statements This presentation contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, ‘These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ

  5. Slide 5: Peter Greenleaf, Chief Executive Officer

    15 Corporate Update Peter Greenleaf Chief Executive Officer § SUCAMPO ‘The Science of Innovation .S

  6. Slide 6: Revenue Growth, Earnings Growth

    Revenue Growth Earnings Growth $9.3 $9.6 $6.4 $2.3 — $1.6 $0.6 3-1 414 at Otis 0414 ans ats 02-14 C215 1 Product Royalty/Product Sales «Other, including milestones Raising 2015 Guidance | + $30 - $35M for net income ¢ 6 + $0.65 - $0.75 per diluted share 3 SUCAMPO — a ~ ‘The Science of Innovation In

  7. Slide 7: Continued Financial Performance

    Continued Financial Performance Significant gains drove strong financial performance + Overall revenue grew 45% + Product royalty revenue grew 16% + Product sales revenue grew 92% Net income and EPS + Net income: $9.6M, increased 495% + EPS: $0.21, increased 425% SUCAMPO ‘The Science of Innovation w

  8. Slide 8: U.S. AMITIZA Performance

    U.S. AMITIZA Performance Takeda AMITIZA net sales* + Increased 15% to $88.2M Sucampo AMITIZA revenue + Royalty revenue grew 16% AMITIZA prescriptions + 363,000 TRx’s, increased 10% + New Rx grew 13% + Highest quarter of prescriptions since launch Constipation category grew 7% SUCAMPO . “Reported by

  9. Slide 9: Japan AMITIZA Performance

    Japan AMITIZA Performance Sucampo revenue + Sales grew 101% to $14.5M Mylan committed to brand growth * Significant detailing levels * Brand “launch” ww SUCAMPO id ‘The Science of Innovation

  10. Slide 10: AMITIZA Globally

    AMITIZA Globally Asia + — Entered into exclusive agreement with Harbin Gloria Pharmaceuticals for AMITIZA in China + — June: Acceptance of IND for AMITIZA in CIC by the CFDA + Recognized $1.5M upfront payment Europe + Austria, Germany and Italy issued NMA + Ireland, Luxembourg, the Netherlands and B

  11. Slide 11: Evaluation of External Assets

    ion of External Assets Assessment of external programs ongoing Complement existing product pipeline Accretive in short term Leverage current skills and Specialty focus experience $ sucampo " ‘The Science of Innovation

  12. Slide 12: Pipeline Update

    line Update Peter Kiener, D. Phil Chief Scientific Officer § SUCAMPO ‘The Science of Innovation .S

  13. Slide 13: Pediatric Functional Constipation (PFC) 6-17 Years

    Pediatric Functional Constipation (PFC) 6-17 Years Enrollment continues at development sites across the U.S., Europe in single pivotal clinical trial Data expected in 1H16 Expect to file NDA in 2H16 SUCAMPO e ‘The Science of Innovation ww

  14. Slide 14: AMITIZA Alternate Formulation & PFC 6 Months-6 Years

    AMITIZA Alternate Formulation & PFC 6 Mos=6;Yrs Expect to initiate P3 study in adult CIC patients in 2H15 + Data expected in 1H16 + Expect to file NDA in 2H16 Single pivotal trial in children (6 months-6 years) to commence once alternate formulation is available + Expect to initiate in 1H16 + Expect

  15. Slide 15: Cobiprostone for PPI-Refractory NERD/GERD

    Cobiprostone for PPI-Refractory NERD/GERD Phase 2 study underway + 140-person randomized, double-blind, placebo-controlled, multicenter study * 14 week study comprising a total of 8 weeks of treatment Expect to announce top-line data in 1H16 ww SUCAMPO i ‘The Science of Innovation

  16. Slide 16: Cobiprostone for Oral Mucositis

    Cobiprostone for Oral Mucositis U.S. FDA Fast Track Designation granted in May FDA accepted IND application for P2a clinical trial Expect dosing of patients soon SUCAMPO se ‘The Science of Innovation ww

  17. Slide 17: Financial Performance Update

    rformance Update Andrew Smith Chief Financial Officer § SUCAMPO ‘The Science of Innovation .S

  18. Slide 18: Significant Non-GAAP Earnings Growth

    Significant Non-GAAP Earnings Growth Q2-14 Q2-15 EBITDAS $ sucAMPO "8 In millions of USD The Science of Innovation

  19. Slide 19: Cost of Goods Sold, R&D, G&A and S&M Expenses

    $7.3 $7.1 | Q2-14 Q2-15 Q2-14 Q2-15 Q2-14 Q2-15 Q2-14 Q2-15 Cost of Goods Sold R&D Expenses G&A Expenses S&M Expenses - $ sucAMPO 9 In millions of USD ‘The Science of Innovation

  20. Slide 20: Improvements in Effective Tax Rate

    Improvements in Effective Tax Rate 53% Q2-14 = Q2-15 ¢ 20 ? SUCAMPO ‘The Science of Innovation

  21. Slide 21: Strong Balance Sheet

    Strong Balance Sheet | item | asof 063015 | Change | As of 06/30 Cash, Cash Equivalents, $127.7 $24.1M $103.6M Restricted Cash and Investments. Notes Payable ($21.7M) $27.8M ($49.5M) Cash, Cash Equivalents, $106.0M $51.9M $54.1M Restricted Cash and Investments, net of Debt Six Months ix Months Endin

  22. Slide 22: Peter Greenleaf, Chief Executive Officer

    Peter Greenleaf Chief Executive Officer § SUCAMPO ‘The Science of Innovation .S

  23. Slide 23: Continuing to Make Progress on 2015 Expectations

    Continuing to Make Progress on 2015 Expectations ¥ Outstanding financial performance v Advancing our pipeline v Evaluating opportunities for long-term growth SUCAMPO 2 ‘The Science of Innovation ww

  24. Slide 24: ? SUCAMPO

    ¢ 24 ? SUCAMPO ‘The Science of Innovation

Sucampo Pharmaceuticals — Q2 2015 Earnings Presentation on 6ix